Literature DB >> 18996661

Towards the clinical application of X-ray phase contrast imaging.

I M Williams1, K K W Siu, R Gan, G Runxuan, X He, S A Hart, C B Styles, R A Lewis.   

Abstract

Synchrotron-based propagation-based imaging, a type of phase contrast imaging, produces better soft tissue image contrast than conventional radiography. To determine whether the technique is directly transferable to the clinical environment for routine diagnostic or screening imaging, a micro-focus (100 microm spot-size) Molybdenum X-ray source with 0.03 mm molybdenum filtration was installed at a local hospital. Breast tissue samples, excised masses and mastectomies, were obtained directly from surgery and imaged at three geometries. The first geometry was optimised for visualizing phase contrast effects using a ray-line argument, the second was the same as that employed by Konica-Minolta in their commercial phase contrast system, and the third was the conventional contact arrangement. The three images taken of each tissue sample were comparatively scored in a pair-wise fashion. Scoring was performed by radiologist expert in mammography, general radiologists, associated clinicians and radiographers on high-resolution mammography rated monitors at two separate locations. Scoring indicated that the optimised and Konica geometries both outperformed the conventional mammographic geometry. An unexpected complication within the trial was the effect that the scoring platform and the associated display tools had on some of the scorer's responses. Additionally, the trial revealed that none of the conventional descriptors for image quality were adequate in the presence of phase contrast enhancements.

Mesh:

Year:  2008        PMID: 18996661     DOI: 10.1016/j.ejrad.2008.04.042

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Analytical reconstructions of intensity modulated x-ray phase-contrast imaging of human scale phantoms.

Authors:  Bartłomiej Włodarczyk; Jakub Pietrzak
Journal:  Biomed Opt Express       Date:  2015-10-05       Impact factor: 3.732

2.  X-ray phase-contrast imaging of the breast--advances towards clinical implementation.

Authors:  S D Auweter; J Herzen; M Willner; S Grandl; K Scherer; F Bamberg; M F Reiser; F Pfeiffer; K Hellerhoff
Journal:  Br J Radiol       Date:  2014-02       Impact factor: 3.039

3.  Feasibility testing of a pre-clinical coded aperture phase contrast imaging configuration using a simple fast Monte Carlo simulator.

Authors:  Anthony Kavanagh; Alessandro Olivo; Robert Speller; Borivoj Vojnovic
Journal:  Biomed Opt Express       Date:  2013-12-04       Impact factor: 3.732

4.  Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup.

Authors:  Julius Emons; Peter A Fasching; Marius Wunderle; Felix Heindl; Jens Rieger; Florian Horn; Georg Pelzer; Andre Ritter; Thomas Weber; Marcus Radicke; Iris Polifka; David L Wachter; Evelyn Wenkel; Thilo Michel; Michael Uder; Arndt Hartmann; Gisela Anton; Matthias W Beckmann; Rüdiger Schulz-Wendtland; Sebastian M Jud
Journal:  Ther Adv Med Oncol       Date:  2020-09-18       Impact factor: 8.168

Review 5.  [Phase contrast imaging of the breast. Basic principles and steps towards clinical implementation].

Authors:  S Grandl; A Sztrókay-Gaul; S D Auweter; K Hellerhoff
Journal:  Radiologe       Date:  2014-03       Impact factor: 0.635

6.  Development and preclinical evaluation of a patient-specific high energy x-ray phase sensitive breast tomosynthesis system.

Authors:  Muhammad U Ghani; Xizeng Wu; Laurie L Fajardo; Zhengxue Jing; Molly D Wong; Bin Zheng; Farid Omoumi; Yuhua Li; Aimin Yan; Peter Jenkins; Stephen L Hillis; Laura Linstroth; Hong Liu
Journal:  Med Phys       Date:  2021-04-01       Impact factor: 4.071

7.  Signs analysis and clinical assessment: phase-contrast computed tomography of human breast tumours.

Authors:  Wushuai Jian; Mingshu Wu; Hongli Shi; Liting Wang; Lu Zhang; Shuqian Luo
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.